Guardant Health, Inc. (Nasdaq: GH), a cutting-edge precision oncology company, is pleased to announce its attendance at the upcoming 41st Annual J.P. Morgan Healthcare Conference. On Monday, January 9th, Guardant Health’s management team will be presenting and answering questions in a Q&A session, which starts at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. Don’t miss out on this exciting opportunity to learn more about the innovative practices Guardant Health is pioneering in the oncology field!
About Guardant Health
Guardant Health is revolutionizing the fight against cancer with its precision oncology platform. Through its proprietary tests, vast data sets, and advanced analytics, it is helping to conquer cancer globally. Its tests such as Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® are being commercially used to improve patient clinical outcomes and lower healthcare costs. Furthermore, its Shield™ test is designed to address the needs of individuals eligible for cancer screening. Guardant Health is truly leading the way in the fight against cancer.